bronchodilatation, 1 reduction in diurnal variation in peak expiratory flow, improvement in Background -Salbutamol is the most widely prescribed short acting 2 agonist daytime and nocturnal symptoms, reduction in requirement for a short acting bronchodilator, 2 3
for the relief and prophylaxis of broncho-as required, and three inhaled salbutamol as an exacerbation of asthma in the previous four mediately after the final challenge to reverse bronchoconstriction, and were allowed to leave weeks. None had been admitted to hospital for an exacerbation of asthma in the previous 12 when their FEV 1 had returned to at least 80% of its baseline value. months. The study was approved by the Royal Postgraduate Medical School and Hammersmith Hospital Research ethics committee and written informed consent was obtained ,      from each subject prior to entry into the study.
Spirometric measurements were made using a dry wedge bellows spirometer (Vitalograph, Vitalograph Ltd, Buckingham, UK) and per-  The study was of a randomised, crossover, formed according to American Thoracic Society guidelines. 17 The highest of a minimum double blind, double dummy design. Subjects attended the laboratory for a screening visit of three technically acceptable measurements from a maximum of eight attempts was reand five study visits at the same time of day, with a washout period of at least three days corded. The two largest values from each set of measurements were required to be rebetween each attendance. Short acting 2 agonists were discontinued for at least six hours producible to within 5%.
Study medication (supplied by Glaxo Group before each attendance. Subjects were also asked to avoid tea and coffee for the same Research, Greenford, Middlesex, UK) was delivered from blinded metered dose inhalers via period because of the possible bronchodilator effects of caffeine. 16 At screening a medical a large volume spacer (Volumatic, Allen & Hanburys Ltd, Uxbridge, Middlesex, UK). history was taken and methacholine challenge was performed. Subjects participated in the Subjects wore nose clips and were instructed to breathe in and out through the valve in the study if they had a provocative concentration of methacholine causing a 20% fall in FEV 1 spacer five times to maximise drug delivery.
Methacholine responsiveness was assessed (PC 20 FEV 1 ) of Ζ8 mg/ml and a shift in PC 20 FEV 1 of more than two doubling con-by a standardised challenge technique similar to that previously described. 18 Methacholine centration steps 30 minutes after inhalation of salbutamol 400 g, while remaining Ζ64 mg/ (Sigma, Poole, UK) aerosol was delivered via Mefar dosimeter (Brescia, Italy) driven by comml. Baseline FEV 1 at each study visit was required to be [65% of the predicted value and pressed air at a pressure of 1.5 kg/m 2 with a one second actuation time and five seconds to not deviate by more than 15% from the screening value. Baseline PC 20 FEV 1 at each breath-hold. Output of the dosimeter was 11 l per puff. At each challenge subjects inhaled visit was required to be within two concentration steps lower or one higher than the five puffs of diluent (isotonic saline) followed by five puffs of doubling concentrations of screening value, and Ζ8 mg/ml. If these criteria were not met an appointment was made for methacholine solution (minimum 0.0625 mg/ ml, maximum 128 mg/ml) until a 20% rereattendance on another day.
On each study day baseline bronchial chal-duction in FEV 1 occurred or the highest concentration was administered. Measurements of lenge with methacholine was performed. One hour after commencing the challenge subjects FEV 1 were made 90 seconds after aerosol inhalation and subsequent doses of methainhaled the study drug (salmeterol 25 g or 100 g, salbutamol 100 g or 400 g, or choline were given at three minute intervals.
In order to abbreviate the challenge procedure, placebo). This was administered in a randomised, double blind, double dummy fashion. and since the algorithm used to calculate the provocative dose causing a 20% fall in FEV 1 Further methacholine challenges were performed 30 and 120 minutes following drug (PD 20 FEV 1 ) utilises only the concentrations of the two highest doses given, 19 study challenges administration. In addition, FEV 1 was measured 90 minutes after dosing. At each visit were started at methacholine concentrations three dose steps lower than that achieved at subjects inhaled salbutamol 400 g imgroup.bmj.com on April 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from changes in baseline methacholine responsive- are shown in table 2. Tests for carry over and two-factor interactions with treatment were non-significant. screening or at 0.0625 mg/ml, whichever was At 30 minutes after medication, prior to the higher. As a safety precaution, salbutamol second bronchial challenge, mean FEV 1 was by nebuliser was always immediately available reduced after placebo (due to persistent for rapid reversal of bronchoconstriction if rebronchoconstriction following baseline methaquired.
choline challenge and possible diurnal variation) but increased after salmeterol 100 g, salbutamol 100 g, and salbutamol 400 g. The   absolute change in FEV 1 from baseline was Means were adjusted for baseline patient and significant in favour of all active treatments treatment. PD 20 FEV 1 values for each challenge when compared with placebo (pΖ0.001). The were obtained by linear interpolation from the increase in FEV 1 after salbutamol 400 g was cumulative log dose-response curve for that significantly greater than after salmeterol 25 g challenge. 19 For PC 20 FEV 1 values greater than (absolute difference=0.24 l (95% CI 0.10 to 128 mg/ml a value of 130 mg/ml was assigned.
0.38), p=0.001). There were no other sigAll the data were then logged and analysed nificant differences between treatments. parametrically. The pre-dosing PD 20 FEV 1 and
The lowest FEV 1 achieved during the 30 the nature of the crossover design were taken minute methacholine challenge did not differ into account in the analysis. Carry over, period significantly on any of the study days. On all and sequence effects were also investigated. treatment days mean FEV 1 90 minutes after The slopes of the FEV 1 changes measured dosing was reduced compared with the baseline during each challenge were analysed paravalue due to the preceding methacholine chalmetrically.
lenge, but further recovery occurred by 120 minutes. There was no significant difference between study treatments other than a sigResults nificantly smaller reduction in FEV 1 after salMethacholine challenges were generally well meterol 100 g than after placebo (absolute tolerated, although subject no. 6 became undifference=0.31 l (95% CI 0.12 to 0.50, p= comfortable and required 2.5 mg nebulised sal-0.002). butamol for reversal of bronchoconstriction
The mean FEV 1 120 minutes after salmeterol after the 120 minute challenge following sal-100 g was increased compared with the basemeterol 25 g. Adverse events considered to be line value whereas it was reduced for all other related to study medication were tremor and treatments. However, all active treatments headache in two different subjects, both after showed a significantly smaller reduction in salbutamol 400 g. These side effects are con-FEV 1 than placebo (pΖ0.011). The effect on sistent with the known pharmacology of 2 FEV 1 was significantly greater after salmeterol adrenoceptor agonists. Four subjects were re-100 g than after salmeterol 25 g (absolute quired to attend extra study visits because of difference 0.16 l (95% CI 0.02 to 0.31), p= 0.028), salbutamol 100 g (absolute difference 0.18 l (95% CI 0.04 to 0.32), p=0.015), and salbutamol 400 g (absolute difference 0.16 l (95% CI 0.02 to 0.31), p=0.027). There were no other significant differences between treatments. salbutamol 100 g, salmeterol 25 g, and salmeterol 100 g. In decreasing rank order, potency of the drugs in protection against methacholine challenge at 30 minutes was salbutamol 400 g > salmeterol 100 g > salbutamol 100 g [ salmeterol 25 g. We have compared salmeterol 25 g and 100 g asthma. Maximal observed bronchoprotection group.bmj.com on April 2, 2017 -Published by http://thorax.bmj.com/ Downloaded from was equivalent for salmeterol 100 g and sal-doses cannot be discriminated. 22 In the present study there was a trend for salmeterol 100 g butamol 400 g but was significantly greater for salmeterol 25 g than salbutamol 100 g to exhibit a greater bronchodilator effect than salmeterol 25 g after baseline methacholine (p=0.01). Salmeterol 25 g was equivalent to salbutamol 100 g at 30 minutes but sig-challenge, as shown by FEV 1 at 90 and 120 minutes, though this was not statistically significantly more effective at 120 minutes. At 30 minutes salmeterol 100 g was less effective nificant. There was a trend to greater protection after salbutamol 400 g than after salmeterol than salbutamol 400 g while at 120 minutes it was significantly more effective. The mag-100 g, although this did not achieve statistical significance. We cannot exclude the possibility nitude of protection due to salmeterol increased over the course of 120 minutes, while pro-of a plateau bronchoprotective effect at the higher dose of salbutamol, suggesting that the tection afforded by salbutamol decreased. This is consistent with the known onset and duration relative potency ratio for salmeterol to salbutamol might be slightly less than 1:4. Comof action of these drugs. It is compatible with previous studies showing a slower onset of parison of the effects of 2 adrenoceptor agonists on methacholine responsiveness thereaction of salmeterol and a longer duration of action than salbutamol in human airways in fore offers a sensitive, convenient and reproducible method for comparing potency of vivo 5 7 8 and in vitro. 20 Inevitably there are some limitations to a drugs of this class, and has been recommended as a method for determining equivalence of study of this nature. Only a relatively small number of subjects was studied but the study inhaled medications. 22 23 In vitro studies suggest a fourfold greater design ensured that the pre-drug methacholine challenge was reproducible by determination affinity of salmeterol for 2 receptors and that salmeterol is 2-15 times more potent than of baseline on each treatment day. Subjects were clinically stable throughout the duration salbutamol. 9 20 Previous single dose studies in vivo in humans have suggested a dose equiof the study. Baseline FEV 1 did not differ significantly between study days and was com-valence of salmeterol compared with salbutamol of 2-16, but these studies have largely parable to screening values, so the observed changes in FEV 1 and PD 20 FEV 1 can confidently relied on change in FEV 1 . As discussed above, this is an insensitive method of estimating relbe attributed to drug and dose differences. The study methodology was adequate to distinguish ative potency. A more comprehensive study compared cumulative doses of salbutamol with a fourfold difference in dose for salbutamol. Methacholine challenge at 30 minutes and at three single doses of salmeterol. 11 Heart rate, plasma potassium, QTc interval, and tremor 120 minutes could have been performed on different days to avoid possible cumulative were examined in addition to FEV 1 . This study showed a wide range of dose equivalence values bronchoconstriction, but such a design would be impractical and has not been adopted by (3-13) depending on which parameter was analysed. Our data are compatible with a weightothers. It would be similarly onerous to increase the number of doses of each drug studied to for-weight dose ratio for salmeterol to salbutamol of Ζ1:4 and a molar dose ratio of construct full log dose-response curves.
  
No study has previously reported the Ζ1:3.8. This is the first study to compare directly bronchoprotective effects of salmeterol at exactly these doses and time points but our results protection afforded by two doses of salmeterol and two doses of salbutamol. It agrees with the are in line with those of other workers. Cheung and coworkers 21 reported an acute protective large multicentre clinical studies on which the clinically recommended therapeutic doses of effect of salmeterol 50 g with a 2.3-fold doubling dose increase in PC 20 FEV 1 at one hour, salmeterol are based. 5 6 These data should help to alleviate concerns regarding risks of salwhereas Derom et al 8 found salmeterol 50 g equivalent to salbutamol 200 g with a 1.9-fold meterol in the treatment of asthma proposed on the basis of previous high estimates of its doubling dose increase in PC 20 FEV 1 at one hour. Gongora et al 7 compared the protective relative 2 agonist potency. effects of salmeterol and salbutamol, delivered effects of salmeterol and salbutamol in asthma. 
Dose equivalence and bronchoprotective

